IPP Bureau
Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr
By IPP Bureau - May 21, 2025
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Venus Remedies joins United Nations Global Compact
By IPP Bureau - May 21, 2025
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Lupin to use Honeywell’s HFO technology in inhalers
By IPP Bureau - May 21, 2025
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Tata 1mg optimises e-commerce operations with Unicommerce
By IPP Bureau - May 21, 2025
IICP and Indegene partner to enable more inclusive society
By IPP Bureau - May 20, 2025
IICP is a registered charitable society working in the disability sector since 1974
Zydus Wellness records a growth of 30% in net profit in FY25
By IPP Bureau - May 20, 2025
EBITDA for the period rose by 23.2% to Rs. 3,797 million
Global Health posts Q4 FY25 consolidated PAT at Rs. 101.4 Cr
By IPP Bureau - May 20, 2025
Global Health has posted net profit of Rs. 481.43 crores for the Financial Year ended March 31, 2025
Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali
By IPP Bureau - May 20, 2025
CRL shall invest another Rs. 200 crore for creation of additional beds
Indraprastha Medical Corporation posts Q4 FY25 PAT at Rs. 41.01 Cr
By IPP Bureau - May 18, 2025
Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025
Alivus Life Sciences reports Q4 FY25 PAT at Rs. 141.86 Cr
By IPP Bureau - May 18, 2025
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
By IPP Bureau - May 18, 2025
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital
By IPP Bureau - May 18, 2025
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Sun Pharma gets FDA approval for new device to treat skin disease
By IPP Bureau - May 18, 2025
Punita Lal Joins Lupin Board as Additional Director
By IPP Bureau - May 18, 2025
She has held senior positions at Coca-Cola in China and PepsiCo in India
Lupin receives USFDA approval for Rivaroxaban Tablets
By IPP Bureau - May 18, 2025
